Glaukos Corporation evaluates the rate of clinically relevant complications associated with iStent inject
Photo by Vanessa Bumbeers
The company Glaukos Corporation is enrolling patients into the clinical trial investigating iStent Inject New Enrollment Post-Approval Study.
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
To evaluate the rate of clinically relevant complications associated with iStent inject placement and stability, as determined at 36 months in the postmarket setting.
Patients will be implanted with the iStent Injection Micro-Bypass device.
The study start date is September 22, 2020.
Volunteers must meet the following criteria:
- Male or female at the age 22 years or older
- Mild to moderate primary open-angle glaucoma
- Scheduled to undergo cataract surgery
Operative Inclusion Criterion:
- Successful, uncomplicated cataract surgery
The study will take place at the Eye Doctors of Arizona, PLLC (Phoenix, Arizona, United States, 85003), Wolstan and Goldberg Eye Associates (Torrance, California, United States, 90505) and Glaucoma Associates of Texas (Dallas, Texas, United States, 75231).
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04624698.
